低中危前列腺癌SBRT的Ⅱ期研究:毒性与生活质量报告
该Ⅱ期研究纳入60例低中危前列腺癌患者,接受37 Gy/5次SBRT,中位随访27.6个月。≥3级泌尿毒性未观察到,晚期≥3级胃肠毒性1例(1.7%);性功能相关评分在36个月时显著下降,但泌尿、肠道及激素域无显著差异。结论认为SBRT耐受性良好,需更长随访评估疗效。
要点
- 低中危前列腺癌37 Gy/5次SBRT的晚期≥3级胃肠毒性为1.7%,未观察到≥3级泌尿毒性。
- AUA症状评分治疗中升至11,36个月回落至5,与基线4.5无显著差异。
- 36个月时EPIC简表仅性功能域评分显著下降(67.9 vs 45.2,p=0.02)。
核心结论
- 低中危前列腺癌SBRT耐受性良好,毒性有限且生活质量下降不明显。
- 需更长随访评估疗效。
研究设计与样本
- Ⅱ期研究,2009至2013年纳入60例T1-T2c前列腺癌患者。
- 入组条件为Gleason 6且PSA≤15或Gleason 7且PSA≤10。
- 排除淋巴结转移、AUA症状评分>18或腺体>100 g者。
- 治疗方案为37 Gy分5次,采用实时运动管理和每日计划再优化。
主要发现
- 中位随访27.6个月,未观察到≥3级泌尿毒性。
- 4例(6.7%)报告晚期2级泌尿毒性。
- 1例(1.7%)报告晚期3级胃肠毒性,5例(8.3%)出现晚期2级胃肠毒性。
- AUA症状评分中位值从治疗前4.5升至治疗中11(p<0.01),36个月为5(p=0.65)。
- IIEF中位评分从19降至17(p<0.01);36个月时EPIC简表仅性功能域评分显著下降(67.9 vs 45.2,p=0.02)。
临床怎么用
- 对于低中危前列腺癌,37 Gy/5次SBRT可作为耐受性良好的治疗选择。
- 治疗中AUA症状评分可升高,但36个月多恢复至基线附近。
- 性功能可能下降,需在治疗前咨询中告知患者。
局限性
- 中位随访仅27.6个月,不足以评估长期疗效。
- 样本量60例,单臂Ⅱ期设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical data indicates that delivery of larger daily doses of radiation may improve the therapeutic ratio for prostate cancer compared to conventional fractionation. A phase II study of stereotactic body radiotherapy with real-time motion management and daily plan re-optimization for low to intermediate risk prostate cancer was undertaken to evaluate this hypothesis. This report details the toxicity and quality of life following treatment. METHODS: From 2009 to 2013, 60 patients with T1-T2c prostate cancer with a Gleason score of 6 and PSA ≤ 15 or Gleason score of 7 and PSA ≤ 10 were enrolled. Patients with nodal metastases, an American Urological Association symptom score > 18, or gland size > 100 g were not eligible. Patients were treated to 37 Gy in 5 fractions. Early and late genitourinary and gastrointestinal toxicity were graded based on NCI CTCAE v4.0 and quality of life was assessed by the American Urological Association symptom score, International Index of Erectile Function, and Expanded Prostate cancer Index Composite Short Form up to 36 months after treatment. RESULTS: After a median follow-up of 27.6 months, no grade 3 or greater genitourinary toxicity was observed. Four patients (6.7%) reported a late grade 2 genitourinary toxicity. One patient (1.7%) reported a late grade 3 gastrointestinal toxicity. Five patients (8.3%) developed a late grade 2 gastrointestinal toxicity. The median American Urological Association symptom score increased from 4.5 prior to treatment to 11 while on treatment (p < 0.01), but was 5 at 36 months post-treatment (p = 0.65). Median International Index of Erectile Function scores decreased from 19 to 17 over the course of follow-up (p < 0.01). Only median scores within the Expanded Prostate Cancer Index Composite Short Form sexual domain were significantly decreased at 36 months post-treatment (67.9 vs 45.2, p = 0.02). There was no significant difference in median score within the urinary, bowel, or hormonal domains at 36 months of follow-up. CONCLUSIONS: Stereotactic body radiotherapy for low to intermediate risk prostate cancer is well tolerated with limited toxicity or decrease in quality of life. Longer follow-up is necessary to assess the efficacy of treatment. TRIAL REGISTRATION: Clinicaltrials.gov NCT00941915 Registered 17 June 2009.
引用
- Boyer MJ, Papagikos MA, Kiteley R, et al. Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancer. Radiat Oncol. 2017. PMID: 28086825. doi:10.1186/s13014-016-0758-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。